Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma

Background: Some patients with severe asthma may benefit from treatment with biologics, but evidence has been mostly collected from randomized controlled trials (RCTs), in which patients' characteristics are different from those encountered in asthma patients in the real-world setting. The aim...

Descripción completa

Detalles Bibliográficos
Autores: Basagaña Torrentó, Maria|||0000-0002-5478-5945, Martínez Rivera, Carlos|||0000-0003-1031-2561, Padró-Casas, Clara|||0000-0003-0139-5836, Garcia-Olivé, Ignasi|||0000-0001-7698-5107, Martínez-Colls, Mimar, Navarro, Juan, Pardo, Laura|||0009-0009-9237-0634, Cruz, Paula, Cardona Peitx, Gloria, Carabias, Lídia, Roger, Albert, Abad Capa, Jorge|||0000-0002-8129-7859, Rosell Gratacos, Antoni|||0000-0003-0877-7191
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:304784
Acceso en línea:https://ddd.uab.cat/record/304784
https://dx.doi.org/urn:doi:10.1080/07853890.2024.2317356
Access Level:acceso abierto
Palabra clave:Evere asthma
Biologics
Omalizumab
Benralizumab
Mepolizumab
Retrospective analysis
Descripción
Sumario:Background: Some patients with severe asthma may benefit from treatment with biologics, but evidence has been mostly collected from randomized controlled trials (RCTs), in which patients' characteristics are different from those encountered in asthma patients in the real-world setting. The aim of this study was to describe the clinical features of complete responders versus non-complete responders to long-term treatment with biologics in patients with severe asthma attended in routine daily practice. Methods: Data of a cohort of 90 patients with severe asthma who were treated with biologics (omalizumab, benralizumab, and mepolizumab) for at least 12 months and were followed up to March 2022. Data recorded included clinical characteristics and effectiveness of treatment (exacerbation, Asthma Control Test [ACT] score, lung function, use of maintenance oral corticosteroids [mOCS]), FeNO, and blood eosinophils at baseline, at 12 months, and at the end of follow-up. Complete response is considered if, in addition to not presenting exacerbations or the use of mOCS, the ACT score was.

Similares en LA Referencia